Zai Lab's Zoci Data Outshine A Stalling China Business As Losses Widen And Revenue Growth Slows

Zai Lab's third quarter offered two very different stories. The pipeline took a real step forward. The commercial business, which is supposed to fund that pipeline, barely moved. The company reported a loss of $0.41 per ADS, compared with $0.33 a year earlier, which Earnings Whispers calculates as a 24.2% year-over-year earnings decline. Revenue of $108.21 million edged past the $108.07 million consensus by 0.1% but fell 6.8% from a year ago. Revenue was essentially in line, losses widened, and the case for owning the stock now rests more heavily than ever on zocilurtatug pelitecan (zoci). That is the central tension.

The quality of the quarter deserves scrutiny.

• **Revenue:** Net product revenue rose just 2% sequentially. That is a sharp slowdown from the 11% sequential gain in the second quarter. On a constant-currency basis, product revenue fell 11% year over year, so currency flattered the reported decline.
• **Product mix:** NUZYRA and the June launch of KarXT drove the sequential gain. OPTUNE declined amid what the company called evolving competition in glioblastoma.
• **Costs and margin:** Cost of product revenue rose to $51.3 million from $46.8 million even as sales fell. That increase reflects $13.6 million of inventory write-downs, which management cited as the main reason the net loss grew to $46.1 million from $36.0 million.
• **Operating loss:** The non-GAAP figure is not flattering either. Adjusted loss from operations widened to $47.6 million from $28.0 million, even with share-based compensation down sharply.
• **Support below the line:** A $10.5 million foreign-currency gain cushioned the bottom line, while interest income kept shrinking as cash declined.

The balance sheet explains the October financing. Cash, current restricted cash and short-term investments fell to $659.7 million from $717.5 million in June, continuing a steady slide from roughly $790 million at the end of 2025. The company then raised $250 million gross ($241.2 million net) in a private placement at $22.04 per ADS. On the call, management characterized the deal as priced at no discount to market. The raise extends runway into a catalyst-heavy 2027, but it comes at the cost of dilution.

The call preserved a credible growth story, and it came almost entirely from R&D:

• **First-line small cell lung cancer:** On the second-quarter call, management had framed roughly 80% response as the bar for a first-line win. Zoci plus atezolizumab cleared it, with an 81.8% confirmed ORR in 33 patients, an estimated 81.9% six-month PFS rate, median PFS not reached, and only 9.1% Grade 3+ zoci-related adverse events. A global Phase 3 doublet study is slated to start by year-end.
• **Extrapulmonary neuroendocrine carcinomas (epNEC):** This program moved from "engaging with regulators" to an FDA-supported single-arm accelerated-approval path, with topline data due in the first half of 2027.
• **Second-line SCLC:** The DLLEVATE interim analysis is now defined at roughly 200 patients and could support a U.S. accelerated filing after a second-half 2027 readout.

Management's tone was noticeably more confident, describing this as one of the most important periods in the company's history. It also reaffirmed both a 2028 U.S. launch target and a return to year-over-year growth in 2027.

Bears still have legitimate ammunition. Amgen's tarlatamab programs in first-line SCLC could raise the competitive bar before zoci's Phase 3 reads out. The DLLEVATE interim depends on enrolling enough post-tarlatamab patients. Commercially, Zejula still faces olaparib volume-based procurement pricing, and NRDL pricing outcomes for Cobenfy and VYVGART Hytrulo are pending. Partner argenx also halted the Sjögren's UNITY study of efgartigimod for futility, trimming one regional option, although the positive ALKIVIA myositis data add a potential 2027 China filing. Total revenue remains well below the $127.6 million posted in the fourth quarter of 2025, so the promised 2027 rebound is still a management expectation, not a demonstrated trend.

Investors entered the report in a more skeptical mood. Earnings Whispers sentiment slid from -0.43 to -0.57, a meaningful move further into negative territory, though not a collapse. Price action tells a more constructive story. At $22.80, shares were up 19.7% from the $19.05 open after the August report and about 8.5% above the 200-day moving average of $21.02. They also sat close to the placement price. However, the stock was still 17.1% below the $27.50 52-week high set on August 19, so much of the post-August enthusiasm has already been surrendered. Trend readings are mixed: sequential growth registers positively, while the AVWAP trend remains negative. That pattern fits a stock caught between pipeline optimism and commercial fatigue.

The bottom line is that Zai Lab's quarter was weak on fundamentals and strong on the pipeline. Revenue grew only marginally, write-downs widened losses, and cash kept draining until a dilutive raise refilled it. Against that, zoci's first-line data cleared management's own bar, and the company now has two potential registrational readouts in 2027. The investment setup has become a cleaner bet on zoci's regulatory path. Investors are effectively looking past the China business for now, but management's reaffirmed 2027 growth target will need to show up in the numbers to keep the funding story credible.

Read our earnings preview for Zai Lab Limited: https://www.earningswhispers.com/article/ZLAB/22218

This earnings review was originally published on Earnings Whispers.

This article is for informational purposes only and is not investment advice. Earnings Whispers and its staff may hold positions in the securities mentioned. It is AI-assisted, based on proprietary Earnings Whispers data and company reports, and edited by Earnings Whispers staff.